Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Inhibitor Therapeutics ( (INTI) ).
Inhibitor Therapeutics, Inc., a biopharmaceutical company focused on developing therapeutic products, operates in the life sciences sector with an emphasis on advancing drug candidates for specialized healthcare markets. Its business model depends heavily on securing external financing to support ongoing development and commercialization activities.
On February 24, 2026, Inhibitor Therapeutics reported entering a securities purchase agreement with an institutional investor to sell 12,000,000 common shares and issue warrants for up to 7,000,000 additional shares for a planned $3 million financing. On March 30, 2026, the company initiated litigation against the investor for failing to fund the agreed investment and fulfill its obligations, creating uncertainty around the expected capital infusion and potentially affecting the company’s near-term funding plans and investor confidence.
More about Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products. The company operates in the life sciences sector, with its primary activities centered on advancing drug candidates and related technologies for medical treatments within specialized healthcare markets.
Average Trading Volume: 39,803
Technical Sentiment Signal: Buy
Current Market Cap: $18.77M
For an in-depth examination of INTI stock, go to TipRanks’ Overview page.